Sign In
Buy HCKT
The Hackett Group Earnings Calls
| Release date | Nov 04, 2025 |
| EPS estimate | $0.370 |
| EPS actual | $0.370 |
| Revenue estimate | 71.07M |
| Revenue actual | 72.166M |
| Revenue Surprise | 1.54% |
| Release date | Aug 05, 2025 |
| EPS estimate | $0.380 |
| EPS actual | $0.380 |
| Revenue estimate | 80.759M |
| Revenue actual | 78.899M |
| Revenue Surprise | -2.30% |
| Release date | May 06, 2025 |
| EPS estimate | $0.400 |
| EPS actual | $0.410 |
| EPS Surprise | 2.50% |
| Revenue estimate | 80.959M |
| Revenue actual | 77.865M |
| Revenue Surprise | -3.82% |
| Release date | Feb 18, 2025 |
| EPS estimate | $0.410 |
| EPS actual | $0.470 |
| EPS Surprise | 14.63% |
| Revenue estimate | 80.328M |
| Revenue actual | 79.235M |
| Revenue Surprise | -1.36% |
Last 4 Quarters for The Hackett Group
Below you can see how HCKT performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 18, 2025 |
| Price on release | $31.62 |
| EPS estimate | $0.410 |
| EPS actual | $0.470 |
| EPS surprise | 14.63% |
| Date | Price |
|---|---|
| Feb 11, 2025 | $32.09 |
| Feb 12, 2025 | $31.38 |
| Feb 13, 2025 | $31.87 |
| Feb 14, 2025 | $31.94 |
| Feb 18, 2025 | $31.62 |
| Feb 19, 2025 | $30.78 |
| Feb 20, 2025 | $30.69 |
| Feb 21, 2025 | $30.18 |
| Feb 24, 2025 | $30.21 |
| 4 days before | -1.46% |
| 4 days after | -4.46% |
| On release day | -2.66% |
| Change in period | -5.86% |
| Release date | May 06, 2025 |
| Price on release | $26.01 |
| EPS estimate | $0.400 |
| EPS actual | $0.410 |
| EPS surprise | 2.50% |
| Date | Price |
|---|---|
| Apr 30, 2025 | $25.54 |
| May 01, 2025 | $25.66 |
| May 02, 2025 | $26.32 |
| May 05, 2025 | $26.66 |
| May 06, 2025 | $26.01 |
| May 07, 2025 | $23.94 |
| May 08, 2025 | $24.66 |
| May 09, 2025 | $24.77 |
| May 12, 2025 | $25.60 |
| 4 days before | 1.84% |
| 4 days after | -1.58% |
| On release day | -7.96% |
| Change in period | 0.235% |
| Release date | Aug 05, 2025 |
| Price on release | $22.78 |
| EPS estimate | $0.380 |
| EPS actual | $0.380 |
| Date | Price |
|---|---|
| Jul 30, 2025 | $23.09 |
| Jul 31, 2025 | $23.39 |
| Aug 01, 2025 | $23.00 |
| Aug 04, 2025 | $23.28 |
| Aug 05, 2025 | $22.78 |
| Aug 06, 2025 | $20.72 |
| Aug 07, 2025 | $20.88 |
| Aug 08, 2025 | $20.68 |
| Aug 11, 2025 | $20.47 |
| 4 days before | -1.34% |
| 4 days after | -10.14% |
| On release day | -9.06% |
| Change in period | -11.35% |
| Release date | Nov 04, 2025 |
| Price on release | $17.66 |
| EPS estimate | $0.370 |
| EPS actual | $0.370 |
| Date | Price |
|---|---|
| Oct 29, 2025 | $17.84 |
| Oct 30, 2025 | $18.04 |
| Oct 31, 2025 | $18.11 |
| Nov 03, 2025 | $18.00 |
| Nov 04, 2025 | $17.66 |
| Nov 05, 2025 | $18.94 |
| Nov 06, 2025 | $18.77 |
| Nov 07, 2025 | $18.57 |
| Nov 10, 2025 | $18.43 |
| 4 days before | -1.01% |
| 4 days after | 4.36% |
| On release day | 7.25% |
| Change in period | 3.31% |
The Hackett Group Earnings Call Transcript Summary of Q3 2025
Key points for investors: The Hackett Group reported Q3 revenue before reimbursements of $72.2M (down 7% YoY) and adjusted diluted EPS of $0.37 (midpoint of guidance). GAAP EPS was $0.09, impacted by noncash stock compensation and a $3.1M restructuring charge tied to headcount reductions to align with demand and to capture expected GenAI productivity benefits. GenAI momentum is a major strategic driver: the company launched AI XPLR version 4 and a Celonis alliance, sees strong early reactions from clients/partners, and expects to begin licensing AI XPLR late Q4 or by Q1. The LeewayHertz acquisition contributes ZBrain, and management plans a JV to combine AI XPLR and ZBrain to pursue recurring ARR/licensing opportunities. Q4 guidance: revenue before reimbursements $69.5M–$71.0M, adjusted diluted EPS $0.38–$0.40, adjusted gross margin ~46–47%, adjusted EBITDA margin ~22–23%. Cash and capital allocation: cash $13.9M, total debt $44M, net cash from operations $11.4M this quarter, repurchased ~1.1M shares for $22.9M in Q3, and announced a $40M modified Dutch-tender offer to buy back additional shares (price range $18.30–$21.00). Recurring/subscription revenue is ~23% of total. Management emphasizes that AI XPLR v4 differentiates the company (process-aware, faster ideation to implementation) and expects GenAI-driven demand to accelerate in 2026. Risks noted include prolonged client decision-making (impacting Oracle segment), a nonrenewal IPaaS contract, and near-term seasonality reducing billing days in Q4.
